Nucala is a humanized monoclonal antibody that targets human Interleukin-5 (IL-5), it is indicated for add on maintenance treatment of patients 6 years and older with severe asthma with eosinophilic phenotype.
Inflammation is an important component of asthma development. It is mediated by multiple cell types which include eosinophils, a type of white blood cell that protects the body from parasites, allergens and foreign bacteria.
Eosinophilic inflammation can be characterized by high eosinophilic count via bloodwork. IL-5 is a major cytokine which is responsible for eosinophil development.
Nucala binds and targets IL-5 blocking. IL-5 binds to the alpha chain of the IL-5 receptor complex. This prevents IL-5 signaling, reducing the production and survival of eosinophils.
Click here for additional side effects
Every 4 weeks
Before your infusion, it is important to drink plenty of water and come to your appointment hydrated. Additionally, you must alert us as soon as possible to any changes in your insurance to ensure that we are still an in-network provider for your infusion therapy.